[
  {
    "ts": null,
    "headline": "Columbia Dividend Income Fund Q3 2024 Commentary",
    "summary": "Institutional Class shares of Columbia Dividend Income Fund returned 8.12% for the \nquarter ending September 30, 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=00f44478a7c2c5c5bdfac13b4f48e8cf05839cda2b4c30419cf2a53e60304be9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733351400,
      "headline": "Columbia Dividend Income Fund Q3 2024 Commentary",
      "id": 131773107,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1365758819/image_1365758819.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Institutional Class shares of Columbia Dividend Income Fund returned 8.12% for the \nquarter ending September 30, 2024. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=00f44478a7c2c5c5bdfac13b4f48e8cf05839cda2b4c30419cf2a53e60304be9"
    }
  },
  {
    "ts": null,
    "headline": "Dow 30 December Dogs Show 28 Pay Dividends And 1 \"Safer\" Buy",
    "summary": "While most of this collection of Dow Industrials is too pricey and reveals only skinny dividends, one of the ten lowest priced Dogs of the Dow is ready to buy. Read on to find out which one.",
    "url": "https://finnhub.io/api/news?id=15e66617820a3c8667c0dac86e09c763de246865d1f7e9d08e9f312422bbb1d6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733333838,
      "headline": "Dow 30 December Dogs Show 28 Pay Dividends And 1 \"Safer\" Buy",
      "id": 131770508,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/149130950/image_149130950.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "While most of this collection of Dow Industrials is too pricey and reveals only skinny dividends, one of the ten lowest priced Dogs of the Dow is ready to buy. Read on to find out which one.",
      "url": "https://finnhub.io/api/news?id=15e66617820a3c8667c0dac86e09c763de246865d1f7e9d08e9f312422bbb1d6"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
    "summary": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=8be23f144a009dcff2c0ef5e5f253e4f5afef9a3e6b162cca497dc73bb267a19",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733330100,
      "headline": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
      "id": 131775678,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=8be23f144a009dcff2c0ef5e5f253e4f5afef9a3e6b162cca497dc73bb267a19"
    }
  },
  {
    "ts": null,
    "headline": "HSBC upgrades Merck stock to Buy on 2025 opportunities",
    "summary": "Investing.com -- HSBC analysts raised their rating on Merck &Company Inc (NYSE:MRK) shares to Buy from Hold while maintaining a price target of $130.",
    "url": "https://finnhub.io/api/news?id=88a778221c99545db1182a96e07aa5e1716e1cd77e0c4038b9a545479e2a269e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733322354,
      "headline": "HSBC upgrades Merck stock to Buy on 2025 opportunities",
      "id": 131768068,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Investing.com -- HSBC analysts raised their rating on Merck &Company Inc (NYSE:MRK) shares to Buy from Hold while maintaining a price target of $130.",
      "url": "https://finnhub.io/api/news?id=88a778221c99545db1182a96e07aa5e1716e1cd77e0c4038b9a545479e2a269e"
    }
  },
  {
    "ts": null,
    "headline": "Merck: FDA grants Breakthrough Therapy designation to sacituzumab tirumotecan",
    "summary": "Merck (MRK) announced that the U.S. FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for the treatment of patients with advanced or metastatic nonsquamous non-small cell lung cancer with epidermal growth factor receptor mutations whose disease progressed on or after tyrosine kinase inhibitor and platinum-based chemotherapy. Sac-TMT is an investigational trophoblast cell-surface antigen 2-directed antibody drug conjugate being developed in collaboration with Kelun-Biote",
    "url": "https://finnhub.io/api/news?id=bdac18cc1abb1c70fa9ce68e0f7f1ea3367bef22cb2eb6b60694eb9a9f81a38f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733313012,
      "headline": "Merck: FDA grants Breakthrough Therapy designation to sacituzumab tirumotecan",
      "id": 131768069,
      "image": "https://media.zenfs.com/en/tipranks_452/bd23518bddbecaa2e26b66cd7da7f21e",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) announced that the U.S. FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for the treatment of patients with advanced or metastatic nonsquamous non-small cell lung cancer with epidermal growth factor receptor mutations whose disease progressed on or after tyrosine kinase inhibitor and platinum-based chemotherapy. Sac-TMT is an investigational trophoblast cell-surface antigen 2-directed antibody drug conjugate being developed in collaboration with Kelun-Biote",
      "url": "https://finnhub.io/api/news?id=bdac18cc1abb1c70fa9ce68e0f7f1ea3367bef22cb2eb6b60694eb9a9f81a38f"
    }
  },
  {
    "ts": null,
    "headline": "Cyber Insurance Update: Recent Decisions Addressing Coverage For Cyber Losses",
    "summary": "New Jersey Appellate Court Refuses to Apply Exclusion for 'Hostile/Warlike Action' to NotPetya CyberattackThe start of this year saw an anticlimactic resolution of an insurance coverage dispute over...",
    "url": "https://finnhub.io/api/news?id=e06c65dd7ab2deb0b87bb6055b6e694493bd3b78231b5522df473d0d610abbd8",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733274787,
      "headline": "Cyber Insurance Update: Recent Decisions Addressing Coverage For Cyber Losses",
      "id": 131763154,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "New Jersey Appellate Court Refuses to Apply Exclusion for 'Hostile/Warlike Action' to NotPetya CyberattackThe start of this year saw an anticlimactic resolution of an insurance coverage dispute over...",
      "url": "https://finnhub.io/api/news?id=e06c65dd7ab2deb0b87bb6055b6e694493bd3b78231b5522df473d0d610abbd8"
    }
  }
]